This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +22.98% per year. These returns cover a period from January 1, 1988 through April 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Microcap Article: Archive
ENZ Stock Falls Post Q1 Earnings Amid Revenue and Demand Challenges
by Zacks Equity Research
Enzo Biochem reports a first-quarter fiscal 2025 quarterly loss and revenue drop across regions amid challenges in the life sciences tools market.
biotechnology biotechs earnings medical
ARKR Stock Declines Post Q4 Earnings Amid Revenue Challenges
by Zacks Equity Research
Ark Restaurants reports a fourth-quarter fiscal 2024 quarterly revenue dip and net loss amid costs weighing on margins.
ARKRPositive Net Change
earnings restaurants retail
AXR Stock Dips After Reporting Q2 Earnings, Revenues Surge Y/Y
by Zacks Equity Research
AMREP posts strong revenue growth in second-quarter fiscal 2025, driven by strong land and home sales, but rising costs and market challenges weigh on the outlook.
AXRNegative Net Change
earnings finance real-estate
Value Line Stock Rises 1% Since Q2 Earnings Surging Y/Y
by Zacks Equity Research
VALU's fiscal second-quarter earnings jump 62% year over year, driven by strong EAM revenues and investment gains. Shareholder equity shows strong improvement.
VALUPositive Net Change
earnings finance
AstroNova Stock Plunges 5.8% Since Q3 Earnings Release
by Zacks Equity Research
ALOT's Q3 earnings highlight 7.7% revenue growth, but margin pressures, MTEX integration challenges, and delayed launches weigh on profitability.
ALOTPositive Net Change
business-services earnings
MIND Technology Stock Soars 45% on Strong Q3 Earnings Growth
by Zacks Equity Research
MIND's third-quarter fiscal 2025 earnings growth is driven by improved efficiency, strong order deliveries and strategic execution, signaling sustained profitability ahead.
MINDPositive Net Change
business-services earnings
Frequency Electronics Stock Rises 26% Since Q2 Earnings Release
by Zacks Equity Research
FEIM delivers strong fiscal Q2 earnings due to 16.5% revenue growth, improved margins and record-high backlog, driven by satellite sector gains.
FEIMNegative Net Change
computers earnings tech-stocks
Kewaunee Scientific's Q2 Earnings Rise Y/Y Despite Sales Decline
by Zacks Equity Research
KEQU reports fiscal Q2 earnings growth, driven by strong domestic demand and strategic acquisition of Nu Aire despite revenue challenges.
KEQUPositive Net Change
earnings tech-stocks
IDT Stock Rises on Strong Q1 Earnings, Profit and Revenue Grow
by Zacks Equity Research
IDT posts strong first-quarter fiscal 2025 results with revenue growth in key segments and profit surge, highlighting robust Fintech and NRS performances.
IDTPositive Net Change
communications earnings utilities
Hovnanian Enterprises Q4 Earnings Decline Y/Y, Revenues Up
by Zacks Equity Research
HOV's strategic focus on contracts and land expansion drives strong Q4 growth despite cost and margin pressures.
HOVPositive Net Change
construction earnings
Zacks Initiates Coverage of CPS Technologies With Neutral Recommendation
by Urbashi Dutta
Discover why Zacks, being the first on Wall Street to initiate the stock coverage, rates CPS Technologies as "Neutral." Explore how CPSH is expanding in advanced materials for defense, clean energy and semiconductors but is facing near-term challenges from margin pressures and revenue dips.
CPSHNegative Net Change
earnings tech-stocks
Zacks Initiates Coverage of Universal Health Realty With Outperform Recommendation
by Debanjana Dey
Discover why Zacks rates Universal Health Realty as "Outperform", being the first on Wall Street to initiate coverage on the stock. Explore UHT's strategic expansions, financial health and operational efficiency.
UHTPositive Net Change
finance reit
Zacks December View on Equity Markets
by John Blank
You can also gauge "fair value" by seeing if the share price is over or under the 2025 and 2026 annual EPS lines.
asset-allocation
ZRS Chart of the Month
by John Blank
Info Tech is overpriced, at extreme valuations, now +40% over the median. That is partly an "AI" froth factor. Factor in high tech mega-cap earnings outlooks too.
asset-allocation
December Asset Allocation Guidelines
by John Blank
5 different frameworks specify portfolio risk tolerance: from Risky ???Max Growth??? to Conservative ???Income.??? Choose one that fits you.
asset-allocation
Sell-Side and Buy-Side - Consensus at a Glance
by John Blank
A valuation boost from the attraction of a broad equity risk premium looks OK using Zacks 2025 S&P500 earnings of $275.08.
asset-allocation
Zacks FX 3-Part Consensus to DEC 2025
by John Blank
An index of U.S. companies may lead one to initially assume that the S&P 500 is exclusively dependent on the health of the U.S. economy. In reality, the index is more global than one may think.
asset-allocation
SGU Q4 Loss Wider Than Expected, Revenues Drop 10% Amid Cost Cuts
by Zacks Equity Research
Star Group faces a challenging quarter with revenues down 10% and wider losses. Improved cash reserves and strategic investments aim to offset headwinds.
SGUPositive Net Change
earnings tech-stocks
VLGEA's Q1 EPS Up 10% Y/Y, Digital Sales Drive 4% Revenue Growth
by Zacks Equity Research
Village Super Market posts fiscal Q1 EPS growth driven by digital sales, pharmacy sales and remodeled store success.
VLGEANegative Net Change
earnings retail
Zacks Initiates Coverage of AstroNova With Neutral Recommendation
by Debasmita Chatterjee
Discover why Zacks has given AstroNova a "Neutral" rating, being the first on Wall Street to initiate coverage on the stock. Explore the company's eco-friendly printing innovations and operational efficiencies alongside challenges from rising debt.
ALOTPositive Net Change
business-services
Zacks Initiates Coverage of ImmuCell With Neutral Recommendation
by Urbashi Dutta
Discover why Zacks, being the first on Wall Street to initiate the stock coverage, rates ImmuCell as "Neutral." Explore ImmuCell's market leadership, growth prospects and the game-changing potential of its mastitis treatment nearing FDA approval.
ICCCPositive Net Change
medical
Zacks Initiates Coverage of Jones Soda With Neutral Recommendation
by Urbashi Dutta
Discover why Zacks, being the first on Wall Street to initiate the stock coverage, rates Jones Soda as "Neutral." Explore how JSDA navigates opportunities with health-focused and cannabis-infused drinks despite financial challenges.
JSDANegative Net Change
consumer-staples
Zacks Initiates Coverage of NetSol With Outperform Recommendation
by Urbashi Dutta
Discover why Zacks, being the first on Wall Street to initiate the stock coverage, rates NTWK as "Outperform." Explore NetSol's growth potential with major global contracts and innovative tech, positioning it for success in asset finance and leasing solutions.
NTWKPositive Net Change
tech-stocks
Zacks Initiates Coverage of NRC Health With Neutral Recommendation
by Debasmita Chatterjee
Discover why Zacks has given NRC Health a "Neutral" rating, being the first on Wall Street to initiate coverage on the stock. Dive into the company's AI innovations, strategic partnerships, and financial resilience, along with the challenges of revenue declines, rising debt and stiff competition.
NRCPositive Net Change
business-services
Two Smaller Companies Worthy of Your "Attention"
by Mark Zinski
Here we highlight a small cap and a microcap with Zacks Outperform ratings.
ELTPPositive Net Change PRPOPositive Net Change
genomics pharmaceuticals small-cap